SEC Form 4	
------------	--

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).		obligations may continue. See
--	--	-------------------------------

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	.,	
1. Name and Address of Reporting Person [*] Landry Robert E	2. Issuer Name and Ticker or Trading Symbol <u>REGENERON PHARMACEUTICALS</u> , <u>INC.</u> [REGN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below)
(Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD	3. Date of Earliest Transaction (Month/Day/Year) 04/09/2020	EVP Finance CFO
(Street) TARRYTOWN NY 10591 (City) (State) (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	04/09/2020		M ⁽¹⁾		3,500	A	\$272.7	27,873	D		
Common Stock	04/09/2020		F ⁽¹⁾		2,672	D	\$508.25	25,201	D		
Common Stock	04/13/2020		S ⁽¹⁾		99	D	\$505.6	25,102	D		
Common Stock	04/13/2020		S ⁽¹⁾		38	D	\$506.24	25,064	D		
Common Stock	04/13/2020		S ⁽¹⁾		30	D	\$507.45(2)	25,034	D		
Common Stock	04/13/2020		S ⁽¹⁾		115	D	\$508.54 ⁽³⁾	24,919	D		
Common Stock	04/13/2020		S ⁽¹⁾		170	D	\$509.45 ⁽⁴⁾	24,749	D		
Common Stock	04/13/2020		S ⁽¹⁾		143	D	\$510.43(5)	24,606	D		
Common Stock	04/13/2020		S ⁽¹⁾		156	D	\$511.59 ⁽⁶⁾	24,450	D		
Common Stock	04/13/2020		S ⁽¹⁾		31	D	\$512.58 ⁽⁷⁾	24,419	D		
Common Stock	04/13/2020		S ⁽¹⁾		46	D	\$517.71	24,373	D		
Common Stock								172	I	By 401(k) Plan	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(= 3)	,		, -		-, -, -,	,		,				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) Disp of (I	oosed D) tr. 3, 4	Expiration Date (Month/Day/Year)		Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- Qualified Stock Option (right to buy)	\$272.7	04/09/2020		M ⁽¹⁾			3,500	(8)	09/09/2023	Common Stock	3,500	\$0.0	39,000	D	

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

2. Represents volume-weighted average price of sales of 30 shares of Company stock on April 13, 2020 at prices ranging from \$507.44 to \$507.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.

3. Represents volume-weighted average price of sales of 115 shares of Company stock on April 13, 2020 at prices ranging from \$508.24 to \$508.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.

4. Represents volume-weighted average price of sales of 170 shares of Company stock on April 13, 2020 at prices ranging from \$509.03 to \$509.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.

5. Represents volume-weighted average price of sales of 143 shares of Company stock on April 13, 2020 at prices ranging from \$510.11 to \$510.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.

6. Represents volume-weighted average price of sales of 156 shares of Company stock on April 13, 2020 at prices ranging from \$511.23 to \$511.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.

7. Represents volume-weighted average price of sales of 31 shares of Company stock on April 13, 2020 at prices ranging from \$512.01 to \$512.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price.

8. The stock option award vests in four equal annual installments, commencing one year after the date of grant.

/s/**Robert E. Landry

** Signature of Reporting Person

04/20/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.